Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Multiplexed Molecular Assays Developed for Foodborne Pathogens

By LabMedica International staff writers
Posted on 11 Jun 2012
Seegene Inc., (Seoul, Korea) and DuPont Nutrition and Health (Wilmington, DE, USA) have agreed to jointly develop highly multiplexed assays for the detection of foodborne pathogens.

Seegene is a leading developer of multiplex molecular technologies and diagnostic tests (M-MoDx) and DuPont Nutrition and Health is a leading provider of rapid, molecular diagnostic systems. More...


The novel technologies from Seegene will be combined with the powerful chemistry and analytics of the BAX System from DuPont, which allows for a potential step-change in pathogen testing. The Seegene Dual Priming Oligonucleotide (DPO) technology generates consistently high specificity by eliminating primer competition, and TOCE technology allows the identification of multiple targets in a single dye channel.

The automated BAX system uses leading-edge technology, including polymerase chain reaction (PCR) assays, tableted reagents and optimized media to detect bacteria and other microbes with certainty. Pathogenic organisms, such as Salmonella, Listeria species, pathogenic Escherichia coli, Shiga toxin-producing E. coli (STEC), Campylobacter, Staphylococcus aureus, Vibrio, and yeast, can be assayed at the genetic level, using the power of the PCR.

The DPO technology is a fundamental tool for blocking extension of nonspecifically primed templates, generating assays that are both highly specific and highly sensitive. The TOCE technology enables simultaneous multiplex testing, by using the differences in melting temperatures of designed artificial amplicons. Prior to TOCE, multiplex assays were difficult because even a small variation in amplicon sequences changes the melting temperature (Tm) of the amplicon. TOCE technology overcomes current limitations of Tm analysis and allows testing of multiple targets with one fluorescent label by ensuring that sequence variation does not change the melting temperature.

Seegene's M-MoDx can simultaneously detect multiple targets with high sensitivity, specificity, and reproducibility. These products detect multipathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor, and costs. Jong-Yoon Chun, PhD, founder and chief executive officer of Seegene, said, "By leveraging these novel technologies, we can advance from the current ‘one test, one pathogen’ approach to a ‘one test, many pathogens’ paradigm. This will significantly improve the efficiency and effectiveness of food safety testing, and help to reduce the prevalence of foodborne illness." The combined technologies may have application for both the Public Health laboratories and nosocomial tracing departments.

Related Links:

Seegene Inc.
DuPont Nutrition and Health



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.